Sobi has extended the existing manufacturing agreement with Pfizer for the drug substance for ReFacto
M2 PHARMA-February 16, 2012-Sobi and Pfizer extend supply agreement for ReFacto
AF/XYNTHA(C)2012 M2 COMMUNICATIONS
Last month, Sobi, which markets hemophilia A drug ReFacto
AF in the Nordic region under a collaboration with Pfizer, unveiled a number of planned cost-saving measures, including 70 job cuts, mainly in preclinical research and manufacturing.
such a technique to switch customers from ReFacto
, a biologic used in
The company also offers the cardiovascular drugs Cordarone, Veralan and Zinc; Lodine, Oruvail and Naprelan, antiarthritic medications; the anti-infectives Suprax and Minocin; and Refacto
, a factor VIII treatment for hemophilia A.
Factor product brand names by type Plasma-free Recombinant factor Refacto
, Helixate FS, Kogenate FS, VIII Advate Recombinant Factor VIII Recombinate (PRODUCTS NO LONGER MANUFACTURED: BIOCLATE, HELIXATE, KOGENATE) Plasma-derived Factor VIII Hemofil M, Monarch M, Monoclate P, Alphanate, Humate P, Koate DVI Plasma-Derived von Willebrand- Humate P (may also use Koate DVI containing Factor VIII or Alphanate which contain von Willebrand Factor but are assayed in factor VIII units) Recombinant Factor IX Benefix Plasma-Derived Factor IX Alphanine, Mononine Desmopressin DDAVP, Stimate